NEW YORK CITY, NY — November 13, 2025 — Leads & Copy — Protagenic Therapeutics Inc. (NASDAQ:PTIX) has successfully completed enrollment and dosing in its Phase 1 Multiple Ascending Dose (MAD) study of PT00114, a novel therapeutic for stress-related neuropsychiatric and neurodegenerative disorders.
The study, conducted in healthy volunteers, was designed to assess the safety and tolerability of PT00114 following multiple doses over time.
Dr. Garo Armen, Executive Chairman of Protagenic Therapeutics, stated that all dosing for healthy volunteers in the Phase 1 study has been completed and that the company plans to release a full summation of the safety results analysis by the end of November. The top-line results from the MAD study are expected to be finalized and released by November 30th.
Dr. Armen added that this milestone underscores the company’s commitment to advancing PT00114 as a potential first-in-class therapeutic for individuals suffering from chronic stress and its neurological consequences. Protagenic Therapeutics had previously completed a single ascending dose study in early 2025.
Protagenic Therapeutics Inc. is a biopharmaceutical company focused on developing peptide-based therapeutics targeting the biological pathways underlying stress-related neurological and mood disorders. The company’s lead compound, PT00114, is a synthetic analog of a naturally occurring brain peptide that helps regulate the body’s stress response and emotional equilibrium.
Forward-looking statements in the press release are subject to risks and uncertainties, including those related to the completion, timing, and results of clinical studies.
Alexander K. Arrow, MD, CFA
Chief Financial Officer
Protagenic Therapeutics, Inc.
149 Fifth Ave, Suite 500, New York, NY 10010
Tel: 213-260-4342
Email: alex.arrow@protagenic.com
Source: Protagenic Therapeutics, Inc.
